Insmed Incorporated Forecast, price target & analysts
Insmed Incorporated Target price 2026 - Analyst rating & recommendation
Insmed Incorporated Classifications & Recommendation
Insmed Incorporated Price Target
| Target Price | $202.07 |
| Price | $120.00 |
| Potential | 68.39% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Insmed Incorporated 2027 . The average Insmed Incorporated target price is $202.07. This is 68.39% higher than the current stock price. The highest price target is $255.15 112.63% , the lowest is $170.69 42.24% . | |
| A rating was issued by 30 analysts: 29 Analysts recommend Insmed Incorporated to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2027 of 68.39% . Most analysts recommend the Insmed Incorporated stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
25 Analysts have issued a sales forecast Insmed Incorporated 2026 . The average Insmed Incorporated sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Insmed Incorporated EBITDA forecast 2026. The average Insmed Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Insmed Incorporated Analysts have issued a net profit forecast 2026. The average Insmed Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
25 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Insmed Incorporated...
Current Insmed Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 10 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 10 2026 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Aug 07 2026 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Aug 07 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 07 2026 |
| BMO Capital |
➜
Outperform
|
Initiated | Jul 21 2026 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Jul 15 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 10 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 10 2026 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Aug 07 2026 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Aug 07 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 07 2026 |
|
Initiated
BMO Capital:
➜
Outperform
|
Jul 21 2026 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Jul 15 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
